GET DAILY SIGNALSRecursion Pharmaceuticals (RXRX) Consolidates Near $4 After +27% Quarterly Advance
Key Takeaways
- RXRX traded near $4.03, little changed from roughly $4.12 a month earlier (about a 2% decline), signaling consolidation after a sharp late-summer advance.
- Over the trailing quarter, shares climbed from around $3.18 in early August, a gain of roughly 27%, as investor interest in AI-enabled drug discovery reaccelerated.
- Recursion Pharmaceuticals is a clinical-stage biotech that applies artificial intelligence and machine learning across target discovery, chemistry, and preclinical development.
- Long-term investors focus on pipeline progression, platform collaborations, and cash runway rather than short-term price swings.
- Biotech equities of this profile remain sensitive to clinical data, sector rotation, and shifts in interest-rate expectations.
- For additional context, explore RXRX Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies approach this name by exploring Trending AI Robots.
Market Snapshot for RXRX
Recursion Pharmaceuticals has entered a consolidation phase. Following a strong upward move in mid-September, the stock pulled back and traded within a range through October before settling near $4.03. That level sits modestly below the roughly $4.12 close from about 30 days prior, even though the broader quarterly trend stays positive.
The price action highlights the sentiment-driven volatility common in clinical-stage biotech names tied to the artificial intelligence theme. Investors continue to balance excitement around AI-powered drug discovery with the reality that these early-stage platforms produce limited near-term revenue and hinge on research milestones plus partnership economics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recursion Pharmaceuticals' Business and Competitive Position
Recursion Pharmaceuticals is a clinical-stage biotechnology company based in Salt Lake City, Utah, focused on industrializing drug discovery. Its main asset is the Recursion Operating System, which integrates automated laboratory experiments, high-dimensional biological imaging, and machine-learning models to generate and analyze biological data at scale.
The platform supports work in oncology, neuroscience, rare diseases, and infectious disease, with the goal of identifying novel targets and moving small-molecule programs forward. Recursion maintains strategic ties with technology and pharmaceutical partners, including a long-standing collaboration with NVIDIA on AI and accelerated computing, as well as alliances with major pharma companies. The completed combination with Exscientia strengthened its chemistry and design capabilities and bolstered its standing among AI-first drug-discovery firms.
Recent Developments Shaping RXRX
Over the past 30 days, RXRX price movement has reflected broader market dynamics more than any single catalyst. The stock saw elevated volatility in mid-October, including sessions with above-average volume, before stabilizing toward month-end. This pattern aligns with profit-taking after the sharp gains from the low-$3 range to the low-$4 range in late September.
Sector factors continue to influence sentiment. AI-linked biotech equities remain correlated with the broader technology trade, and smaller biotech names react quickly to changes in interest-rate expectations and risk appetite. For Recursion specifically, investors are tracking the integration of the Exscientia platform, clinical pipeline progress, and the strength of its technology partnerships.
2026 Outlook and Key Factors to Monitor
Looking forward, the main drivers for Recursion Pharmaceuticals center on execution. Clinical data readouts and pipeline advancement will provide concrete evidence of the platform’s ability to deliver viable drug candidates. Updates on partnership economics, licensing deals, and Exscientia integration will also matter. On the macro side, interest-rate trends and capital availability for biotech will affect sector valuations. Competitive moves in AI-driven discovery and balance-sheet strength remain important as well. I’m watching this closely for signs of sustained momentum.
Automated Trading Strategies Worth Exploring
From what I see, Tickeron’s Trending AI Robots page offers a focused look at top-performing automated strategies across thousands of tickers. It highlights bots with varying approaches and timeframes, which can serve as a practical starting point when considering how algorithmic systems are positioned in names like this one. I find reviewing these strategies helpful when assessing data-driven approaches to the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
RXRX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for RXRX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 57 similar instances where the indicator exited the overbought zone. In 55 of the 57 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RXRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RXRX as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for RXRX just turned positive on October 28, 2026. Looking at past instances where RXRX's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
RXRX moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 207 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 116 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.157) is normal, around the industry mean (3.104). P/E Ratio (-3.680) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement